Kringle Pharma (4884) · RiskWorsened
Impact of Potential Competitor Development on Profitability
First written in FY2020. 1 of 2 entries say "Worsened", first in FY2022. Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Competition Risk from Candidate Product Introduction and Competing Products in the Pharmaceutical MarketA theme 20 companies write about · 22 as a headwind · 0 as a tailwind
Kringle Pharma moved to the "Worse" side of this theme in 2022, 1 year after the typical company in this theme (2021).
The whole theme swung hardest in 2025: 4 of 8 companies on the "Worse" side.
4 other companies' latest entry also says "Worsened".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 20 companies compared. The sentences above are computed from all 20.Full recordFilings, disclosures and news, newest first
- FY2022WorsenedAnnual report
「また現在、欧米において急性腎障害を対象とする競合品が第Ⅲ相試験の開発段階にあることから、その動向を注視しつつ、HGFの優位性を示すための開発を進めてまいります。」
急性腎障害領域で欧米の競合品が第Ⅲ相試験段階にあることを新たに具体化し、競合リスクをより明確にしている。 - FY2020First statedAnnual report
「Changes in the development status of competing products in the future may have a significant impact on future profitability.」
Although the company currently believes there are few competing products, changes in competitor development are identified as a risk to future profitability.